- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Pre-symptomatic spinal muscular atrophy (SMA)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 482KB)
Nusinersen – July 2023
Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza®
Last updated
27 October 2023